Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 195

1.

Molecular pathogenesis of meningiomas.

Perry A, Gutmann DH, Reifenberger G.

J Neurooncol. 2004 Nov;70(2):183-202. Review.

PMID:
15674477
2.

Pathological classification and molecular genetics of meningiomas.

Mawrin C, Perry A.

J Neurooncol. 2010 Sep;99(3):379-91. doi: 10.1007/s11060-010-0342-2. Epub 2010 Sep 1. Review.

PMID:
20809251
3.

Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.

Boström J, Meyer-Puttlitz B, Wolter M, Blaschke B, Weber RG, Lichter P, Ichimura K, Collins VP, Reifenberger G.

Am J Pathol. 2001 Aug;159(2):661-9.

4.

Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression.

Weber RG, Boström J, Wolter M, Baudis M, Collins VP, Reifenberger G, Lichter P.

Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14719-24.

5.

Comparative genomic hybridization analysis of genomic alterations in benign, atypical and anaplastic meningiomas.

Arslantas A, Artan S, Oner U, Durmaz R, Müslümanoğlu H, Atasoy MA, Başaran N, Tel E.

Acta Neurol Belg. 2002 Jun;102(2):53-62.

PMID:
12161900
6.

Chromosome 1p and 14q FISH analysis in clinicopathologic subsets of meningioma: diagnostic and prognostic implications.

Cai DX, Banerjee R, Scheithauer BW, Lohse CM, Kleinschmidt-Demasters BK, Perry A.

J Neuropathol Exp Neurol. 2001 Jun;60(6):628-36.

PMID:
11398839
7.

New developments in the pathology of skull base tumors.

Radner H, Katenkamp D, Reifenberger G, Deckert M, Pietsch T, Wiestler OD.

Virchows Arch. 2001 Apr;438(4):321-35. Review.

PMID:
11355165
8.

Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma.

Lusis EA, Watson MA, Chicoine MR, Lyman M, Roerig P, Reifenberger G, Gutmann DH, Perry A.

Cancer Res. 2005 Aug 15;65(16):7121-6.

9.

Pathology and genetics of meningiomas.

Alahmadi H, Croul SE.

Semin Diagn Pathol. 2011 Nov;28(4):314-24. Review.

PMID:
22195409
10.

Genetic changes with prognostic value in histologically benign meningiomas.

Barbera S, San Miguel T, Gil-Benso R, Muñoz-Hidalgo L, Roldan P, Gonzalez-Darder J, Cerda-Nicolas M, Lopez-Gines C.

Clin Neuropathol. 2013 Jul-Aug;32(4):311-7. doi: 10.5414/NP300580.

PMID:
23442303
11.

[Meningiomas: new prognostic factors].

Sanz Esponera J.

An R Acad Nac Med (Madr). 2007;124(2):319-32; discussion 330-2. Spanish.

PMID:
18069599
12.

[The molecular genetics of meningiomas and genotypic/phenotypic correlations].

Dezamis E, Sanson M.

Rev Neurol (Paris). 2003 Sep;159(8-9):727-38. Review. French.

PMID:
13679715
13.

Genetic alterations associated with progression and recurrence in meningiomas.

Pérez-Magán E, Campos-Martín Y, Mur P, Fiaño C, Ribalta T, García JF, Rey JA, Rodríguez de Lope A, Mollejo M, Meléndez B.

J Neuropathol Exp Neurol. 2012 Oct;71(10):882-93.

PMID:
22964784
14.

Anaplastic meningioma: progression from atypical and chordoid morphotype with morphologic spectral variation at recurrence.

Bollag RJ, Vender JR, Sharma S.

Neuropathology. 2010 Jun;30(3):279-87. doi: 10.1111/j.1440-1789.2009.01060.x. Epub 2009 Sep 14.

PMID:
19780983
15.

Loss of DAL-1, a protein 4.1-related tumor suppressor, is an important early event in the pathogenesis of meningiomas.

Gutmann DH, Donahoe J, Perry A, Lemke N, Gorse K, Kittiniyom K, Rempel SA, Gutierrez JA, Newsham IF.

Hum Mol Genet. 2000 Jun 12;9(10):1495-500.

PMID:
10888600
16.

Intratumoral patterns of clonal evolution in meningiomas as defined by multicolor interphase fluorescence in situ hybridization (FISH): is there a relationship between histopathologically benign and atypical/anaplastic lesions?

Sayagués JM, Tabernero MD, Maíllo A, Espinosa A, Rasillo A, Díaz P, Ciudad J, López A, Merino M, Gonçalves JM, Santos-Briz A, Morales F, Orfao A.

J Mol Diagn. 2004 Nov;6(4):316-25.

17.

Reduced expression of schwannomin/merlin in human sporadic meningiomas.

Lee JH, Sundaram V, Stein DJ, Kinney SE, Stacey DW, Golubić M.

Neurosurgery. 1997 Mar;40(3):578-87.

PMID:
9055299
18.

Molecular biological determinations of meningioma progression and recurrence.

Linsler S, Kraemer D, Driess C, Oertel J, Kammers K, Rahnenführer J, Ketter R, Urbschat S.

PLoS One. 2014 Apr 10;9(4):e94987. doi: 10.1371/journal.pone.0094987. eCollection 2014.

19.

Allelic losses at 1p, 9q, 10q, 14q, and 22q in the progression of aggressive meningiomas and undifferentiated meningeal sarcomas.

Lamszus K, Kluwe L, Matschke J, Meissner H, Laas R, Westphal M.

Cancer Genet Cytogenet. 1999 Apr 15;110(2):103-10.

PMID:
10214357
20.

[Meningioma. Classification and grading].

Niedermayer I, Kolles H, Henn W, Zang KD, Steudel WI, Feiden W.

Pathologe. 1997 Sep;18(5):353-8. Review. German.

PMID:
9432670

Supplemental Content

Support Center